Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2808 participants.

Also called NCT05262803

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,808 participants (planned count) (from the registry)
Sponsor
Rikke Sorensen (from the registry)
Registry
  • NCT NCT05262803
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05262803. Randomized; single masking; primary purpose treatment. Start 2022-06-17 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction
Acronym
Dan-DAPT
Intervention (Genetic)
CYP2C19*2/*3
Intervention (Other)
Shorter DAPT duration
Lead sponsor
Rikke Sorensen (class: other)

Record details

Record id
cardio:ct-nct05262803
Content hash
840537a0ce0335f8a765955ae353f0dd17d573a7d824c237c23462740e6a6234